Clinical Trial

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Trial Details
NCT Number NCT06084962
Lead Sponsor He Huang
Collaborators: Yake Biotechnology Ltd.
Conditions Relapse/Refractory Multiple Myeloma
Enrollment 40 participants
Start Date 2023-10-20
Primary Completion 2026-10-20 (estimated)
Study Completion 2026-10-20 (estimated)
Updated on ClinicalTrials.gov 2023-10-16